DENTSPLY SIRONA Launches AI Dental Imaging Tool Smart View, Detect
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy XRAY?
Source: Yahoo Finance
- FDA Approval of New Product: DENTSPLY SIRONA launched Smart View, Detect, the first FDA-cleared AI-powered CBCT diagnostic aid, marking a significant innovation in digital dentistry, despite a 28.5% decline in its stock price over the past year.
- Sales and Income Challenges: First-quarter 2026 sales were $880 million, roughly flat year-over-year, but the company swung from a net income of $20 million to a net loss of $10 million, indicating fragile profitability while maintaining full-year sales guidance of $3.5 billion to $3.6 billion.
- Expanded Distribution Agreement: DENTSPLY SIRONA expanded its U.S. distribution agreement with Atlanta Dental Supply, aiming to enhance market access for its digital dentistry solutions, although facing pressure from larger competitors.
- Advancement of Digital Strategy: The launch of Smart View, Detect integrated with the DS Core platform aims to drive growth in digital platforms and software subscription revenues, yet the conversion from product launches to sustained revenue growth remains a challenge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XRAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 10.960
Low
12.00
Averages
13.04
High
17.00
Current: 10.960
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- FDA Approval of New Product: DENTSPLY SIRONA launched Smart View, Detect, the first FDA-cleared AI-powered CBCT diagnostic aid, marking a significant innovation in digital dentistry, despite a 28.5% decline in its stock price over the past year.
- Sales and Income Challenges: First-quarter 2026 sales were $880 million, roughly flat year-over-year, but the company swung from a net income of $20 million to a net loss of $10 million, indicating fragile profitability while maintaining full-year sales guidance of $3.5 billion to $3.6 billion.
- Expanded Distribution Agreement: DENTSPLY SIRONA expanded its U.S. distribution agreement with Atlanta Dental Supply, aiming to enhance market access for its digital dentistry solutions, although facing pressure from larger competitors.
- Advancement of Digital Strategy: The launch of Smart View, Detect integrated with the DS Core platform aims to drive growth in digital platforms and software subscription revenues, yet the conversion from product launches to sustained revenue growth remains a challenge.
See More
- Revenue and Earnings Performance: DENTSPLY SIRONA reported Q1 revenue of $880 million and adjusted EPS of $0.27, with operating cash flow at $40 million, while the net debt-to-EBITDA ratio stood at 3.3x, indicating financial pressure.
- Restructuring and Innovation Plans: The company is implementing U.S. commercial restructuring, expanded clinical education, and sales training to redirect funds for future commercial and innovation growth, although the benefits of these actions are expected to materialize more in 2027 and beyond.
- 2026 Outlook Unchanged: Management maintained its 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50, reflecting cautious optimism about future performance.
- Market Pressures and Risks: Management highlighted tariffs, sales mix, and dealer destocking as factors pressuring gross margins, yet the company plans to evaluate the timing of share repurchases in the second half to enhance capital allocation flexibility.
See More
- Earnings Performance: Dentsply Sirona reported a Q1 non-GAAP EPS of $0.27, aligning with expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q1 revenue of $880 million, a slight increase of 0.1% year-over-year, beating market expectations by $39.92 million, demonstrating its strong competitive position.
- Future Outlook: Dentsply Sirona maintains its 2026 net sales outlook in the range of $3.5 billion to $3.6 billion, slightly below the $3.58 billion consensus, reflecting confidence in future growth.
- Stock Price Reaction: Following the earnings release, Dentsply Sirona's shares rose by 2%, indicating positive investor sentiment regarding the company's performance and outlook.
See More
- Enhanced Distribution Agreement: Dentsply Sirona has signed an enhanced distribution agreement with Atlanta Dental Supply, effective August 1, allowing the latter to offer Dentsply Sirona's digital dentistry technology solutions, thereby expanding its influence in the U.S. market.
- Strengthened Market Strategy: By partnering with Atlanta Dental Supply, Dentsply Sirona can leverage deep customer relationships in the Southeast to improve market penetration of digital dental products, thus enhancing customer acquisition capabilities.
- Technology Product Expansion: The new agreement enables Atlanta Dental Supply to offer key digital dentistry technologies, including the CEREC system, intraoral scanning, and digital imaging solutions, addressing the market's demand for efficient dental solutions.
- Customer-Centric Execution: Mark Bezjak, Group Vice President, emphasizes that expanding access to digital dentistry technologies is a core element of their commercial strategy, highlighting the importance of trusted distribution partners for customer-centric and localized execution.
See More

Company Announcement: Dent Supply Sirona has announced a new distribution agreement in the U.S. with a dental supply company.
Effective Date: The agreement is set to take effect on August 1.
See More









